N4 Pharma raises capital to fund vaccine delivery system

Writer, Stock Market Wire
Friday, February 8, 2019 - 13:26

Specialist pharmaceuticals company N4 Pharma said it had raised £1.1m via a share issue to fund the development of its delivery system for vaccines and cancer therapeutics.

News shares in the company were issued at 0.4p each.

'We have made continued progress with Nuvec and believe that it has the potential to significantly improve patient outcomes and generate value for investors and partners,' chief executive Nigel Theobald said.

At 1:26pm: (LON:N4P) N4 Pharma Plc Ord 0.4p share price was -2.3p at 10.05p


Related content

N4 Pharma books annual loss amid higher R&D spend

Vaccine and cancer treatment delivery system developer N4 Pharma booked a full-year loss amid higher R&D spending.

Pre-tax losses for the year through December amounted...

Tue, 14/05/2019 - 09:56


N4 Pharma to kick of new experiments for vaccine delivery product

N4 Pharma said it planned to conduct new and altered experiments for its vaccine delivery product, after original tests produced inconsistent efficacy results.

The company...

Mon, 15/04/2019 - 08:33


N4 Pharma to continue collaboration with MedImmune

N4 Pharma, which is developing a delivery system for vaccines and cancer treatments, said project partner MedImmune had committed to furthering its work with the...

Mon, 05/11/2018 - 13:47


N4 Pharma to close generic division and halt development of specific assets

N4 Pharma undertook a strategic review on sildenafil and decided to discontinue the further development of its assets and close the generic division.

On 9...

Thu, 20/09/2018 - 07:24


N4 Pharma trial of erectile dysfunction treatment fails to meet objectives

N4 Pharma said early results from a clinical trail of a reformulation of erectile dysfunction treatment sildenafil had not met their objectives.

The product formulation...

Mon, 09/07/2018 - 09:08